利生奇珠单抗治疗活动性银屑病关节炎的疗效与安全性:KEEPsAKE 2 研究 52 周结果
KEEPsAKE 2 是一项正在进行的 3 期试验,活动性银屑病关节炎患者按 1:1 随机接受利生奇珠单抗 150 mg 或安慰剂皮下注射。第 24 周利生奇珠单抗组 ACR20 应答率 51.3% vs 安慰剂组 26.5%(P < 0.001);第 52 周持续利生奇珠单抗组 ACR20 应答率 58.5%,第 24 周由安慰剂转换者 55.7%。利生奇珠单抗耐受良好,第 24 至 52 周安全性特征一致。
要点
- 第 24 周利生奇珠单抗组 ACR20 应答率 51.3%(n = 224)vs 安慰剂组 26.5%(n = 220),P < 0.001。
- 第 52 周持续利生奇珠单抗组 ACR20 应答率 58.5%,第 24 周由安慰剂转换组 55.7%。
- 严重治疗中出现的不良事件及导致停药的治疗中出现的不良事件发生率至第 52 周保持稳定,未报告死亡。
核心结论
- 利生奇珠单抗耐受良好,改善对生物制剂应答不佳/不耐受或对传统合成改善病情抗风湿药应答不佳/不耐受的银屑病关节炎患者的症状,第 24 至 52 周长期安全性特征一致。
研究设计与样本
- 正在进行的 3 期 KEEPsAKE 2 试验,活动性银屑病关节炎患者按 1:1 随机接受皮下利生奇珠单抗 150 mg 或安慰剂,分别在第 0、4、16 周给药(第 1 期)。
- 第 24 周(第 2 期)安慰剂组患者转换为利生奇珠单抗,所有患者从第 28 至 208 周每 12 周接受利生奇珠单抗 150 mg。
- 纳入对一种或两种生物制剂应答不佳/不耐受或对一种或多种传统合成改善病情抗风湿药应答不佳/不耐受的活动性银屑病关节炎患者。
主要发现
- 第 24 周,利生奇珠单抗组 51.3%(n = 224)达到 ACR20 应答 vs 安慰剂组 26.5%(n = 220;P < 0.001)。
- 第 52 周,随机接受持续利生奇珠单抗的患者中 58.5% 达到 ACR20,第 24 周由安慰剂转换为利生奇珠单抗的患者中 55.7% 达到 ACR20。
- 其他疗效指标观察到相似趋势。
- 严重治疗中出现的不良事件及导致停药的治疗中出现的不良事件发生率至第 52 周保持稳定,未报告死亡。
关键数值与推荐
- 第 24 周 ACR20 应答率:利生奇珠单抗组 51.3%(n = 224)vs 安慰剂组 26.5%(n = 220),P < 0.001。
- 第 52 周 ACR20 应答率:持续利生奇珠单抗组 58.5%,第 24 周由安慰剂转换组 55.7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: PsA is a chronic inflammatory disease in which the skin and joints are affected. In this follow-up analysis, the 52-week efficacy and safety of risankizumab 150 mg in patients with active PsA who had previous inadequate response/intolerance to one or two biologic therapies (Bio-IR) or one or more conventional synthetic DMARDs (csDMARD-IR) were evaluated. METHODS: In the ongoing, phase 3, KEEPsAKE 2 trial, patients with active PsA were randomized 1:1 to receive subcutaneous risankizumab 150 mg or placebo at weeks 0, 4 and 16 (period 1). At week 24 (period 2), patients who received placebo were switched to risankizumab, and all patients received risankizumab 150 mg every 12 weeks from weeks 28 to 208. RESULTS: At week 24, 51.3% of risankizumab-treated patients (n = 224) achieved ≥20% improvement in ACR criteria (ACR 20) vs 26.5% of placebo-treated patients (n = 220; P < 0.001). At week 52, 58.5% of patients randomized to receive continuous risankizumab achieved ACR20, and 55.7% of patients who switched from placebo to risankizumab at week 24 achieved ACR20. Similar trends were observed for other efficacy measures. Rates of serious treatment-emergent adverse events (TEAEs) and TEAEs leading to discontinuation remained stable through week 52, and no deaths were reported. CONCLUSION: Risankizumab was well tolerated and improved symptoms of PsA in Bio-IR/csDMARD-IR patients, with a consistent long-term safety profile from weeks 24 to 52. TRIAL REGISTRATION: United States National Library of Medicine clinical trials database www.clinicaltrials.gov; KEEPsAKE 2; NCT03671148.
引用
- Östör A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study. Rheumatology (Oxford). 2023. PMID: 36282537. doi:10.1093/rheumatology/keac605
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。